Search results
Results from the WOW.Com Content Network
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. [ 4 ] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [ 5 ] including the United States and Europe. [ 4 ]
Kiran Mazumdar-Shaw (born 23 March 1953) is an Indian billionaire entrepreneur. [3] She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, [4] a biotechnology company based in Bangalore, India [5] and the former chairperson of Indian Institute of Management, Bangalore. [6]
A stock split or stock divide increases the number of shares in a company. For example, after a 2-for-1 split, each investor will own double the number of shares, and each share will be worth half as much. A stock split causes a decrease of market price of individual shares, but does not change the total market capitalization of the company ...
Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall ...
For example, when Agilent Technologies was spun off from Hewlett-Packard (HP) in 1999, the stockholders of HP received Agilent stock. A company not considered a spin-off in the SEC's definition (but considered by the SEC as a technology transfer or licensing of technology to the new company) may also be called a spin-off in common usage.
Spokespersons for Biocon and Viatris Inc, the company which was formed after combining Mylan with Pfizer Inc's off-patent branded drugs business, said that the companies do not comment on market ...
A split share corporation is a corporation that exists for a defined period of time to transform the risk and investment return (capital gains, dividends, and possibly also profits from the writing of covered options) of a basket of shares of conventional dividend-paying corporations into the risk and return of the two or more classes of publicly traded shares in the split share corporation.
India-based Biocon Ltd is reportedly in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website Moneycontrol reported, citing sources with direct ...